Trial Profile
A Phase I, Non-Randomized, Open Label, Single Dose-Escalation Safety Study of Recombinant Human Glucocerebrosidase (prGCD) in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Taliglucerase alfa (Primary)
- Indications Gaucher's disease
- Focus Adverse reactions
- Sponsors Protalix Biotherapeutics
- 19 Jun 2014 New trial record